# US 2023/0406933 A1 · Immune checkpoint inhibitor > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2023/0406933 A1 - Document ID: US20230406933A1 - Status: Published application - Kind: A1 - Application number: 18/035,070 - Filed: 2021-11-02 - Published: 2023-12-21 - Earliest claimed: 2020-11-03 - Assignees: Randox Laboratories Limited - Applicants: Randox Laboratories Ltd. - Inventors: Marshall Dunlop; Shirley Schon; John Lamont; Peter Fitzgerald - Web page: https://patentgrep.com/patent/US20230406933A1 ## CPC - C07K 16/2827: {against B7 molecules, e.g. CD80, CD86} - C07K 2317/22: from camelids, e.g. camel, llama or dromedary - C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity - C07K 2317/622: Single chain antibody (scFv) - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The present invention relates to therapeutic antibodies, or antigen-binding portions thereof, for use in the treatment of cancer and infectious disease. Specifically, the present invention relates to therapeutic antibodies, or antigen-binding portions thereof, that target the programmed death-ligand 1 polypeptide. The present invention also relates to pharmaceutical compositions comprising said therapeutic antibody, or antigen-binding portions thereof. ## Claims ### Claim 1 An antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof has at least 80% sequence identity to SEQ ID NO: 7, and wherein the antibody or antigen-binding portion thereof can specifically bind a programmed death-ligand 1 (PD-L1) polypeptide, and wherein the antibody or antigen-binding portion thereof comprises one or more heavy chain CDRs, wherein (i) a heavy chain CDR1 has at least 70% sequence identity to SEQ ID NO: 1, (ii) a heavy chain CDR2 has at least 70% sequence identity to SEQ ID NO: 2 and (iii) a heavy chain CDR3 has at least 70% sequence identity to SEQ ID NO: 3. ### Claim 2 (depends on 1) The antibody or antigen-binding portion thereof of claim 1, wherein the heavy chain CDR3 has the amino acid sequence according to SEQ ID NO: 36. ### Claim at position 3 3-8. (canceled) ### Claim 9 (depends on 1) The antibody or antigen-binding portion thereof of claim 1, wherein the antibody or antigen-binding portion thereof has a Kd value of between 0.3 and 0.6 nM, preferably between 0.4 and nM, even more preferably between 0.4 and 0.5 nM. ### Claim 10 (depends on 1) The antibody or antigen-binding portion thereof of claim 1, wherein the antibody or antigen-binding portion thereof is a single domain antibody, preferably wherein the antibody or antigen-binding portion thereof is a single heavy-chain variable domain antibody. ### Claim 11 (depends on 1) The antibody or antigen-binding portion thereof of claim 1, wherein the antibody or antigen-binding portion thereof is a human or humanized antibody or antigen-binding portion thereof. ### Claim 12 (depends on 1) The antibody or antigen-binding portion thereof of claim 1, wherein the antibody or antigen-binding portion thereof forms part of a fusion protein or a bispecific antibody. ### Claim 13 (depends on 1) A nucleic acid encoding the antibody or antigen-binding portion thereof of claim 1, or a complementary sequence thereof. ### Claim 14 (depends on 1) A method of treatment comprising administering the antibody or antigen-binding portion or nucleic acid thereof of claim 1 to a subject in need thereof. ### Claim 15 (depends on 14) The method of claim 14, wherein the treatment is a treatment of cancer, and wherein the cancer is a tumour present within the central nervous system (CNS) or wherein the cancer is a solid tumour. ### Claim 16 (depends on 12) The method of claim 12, wherein the treatment is a treatment of an infectious disease. ### Claim 17 (depends on 1) A pharmaceutical composition comprising the antibody or antigen-binding portion thereof or the nucleic acid of claim 1, wherein the composition additionally includes a pharmaceutically acceptable carrier and/or a known therapeutic agent. ### Claim 18 (depends on 1) The antibody or antigen-binding portion thereof according to claim 1, wherein the antibody or antigen-binding portion thereof has at least 85% sequence identity to SEQ ID NO: 7, more preferably at least 90% sequence identity to SEQ ID NO: 7, more preferably at least 95% sequence identity to SEQ ID NO: 7. ### Claim 19 (depends on 1) The antibody or antigen-binding portion thereof according to claim 1, wherein the heavy chain CDR1 has at least 75% sequence identity to SEQ ID NO: 1, more preferably at least 80% sequence identity to SEQ ID NO: 1, more preferably at least 85% sequence identity to SEQ ID NO: 1, more preferably at least 90% sequence identity to SEQ ID NO: 1, more preferably at least 95% sequence identity to SEQ ID NO: 1. ### Claim 20 (depends on 1) The antibody or antigen-binding portion thereof according to claim 1, wherein the heavy chain CDR2 has at least 75% sequence identity to SEQ ID NO: 2, more preferably at least 80% sequence identity to SEQ ID NO: 2, more preferably at least 85% sequence identity to SEQ ID NO: 2, more preferably at least 90% sequence identity to SEQ ID NO: 2, more preferably at least 95% sequence identity to SEQ ID NO: 2. ### Claim 21 (depends on 1) The antibody or antigen-binding portion thereof according to claim 1, wherein the heavy chain CDR3 has at least 75% sequence identity to SEQ ID NO: 3, more preferably at least 80% sequence identity to SEQ ID NO: 3, more preferably at least 85% sequence identity to SEQ ID NO: 3, more preferably at least 90% sequence identity to SEQ ID NO: 3, more preferably at least 95% sequence identity to SEQ ID NO: 3.